Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Verenkierron komplikaatiot munuaissiirron jälkeen (DAN-PTRAIII)

maanantai 12. lokakuuta 2026 päivittänyt: University of Aarhus

Verenkiertoelimistön komplikaatiot munuaissiirron jälkeen: prospektiivinen kansallinen monikeskustutkimus - DAN-PTRAIII-tutkimus

  • To determine the incidence of arterial inflow problems and venous outflow problems as causes of impaired renal function and/or treatment-resistant hypertension after kidney transplantation, when all kidney-transplant recipients in Denmark are evaluated according to uniform, well-defined clinical criteria.
  • To investigate the efficacy and safety of catheter-based balloon treatment (percutaneous transluminal angioplasty, PTA) for these vascular complications, of which transplant renal artery stenosis is by far the most common.
  • To assess whether novel imaging and functional diagnostic methods can predict treatment response.

Tutkimuksen yleiskatsaus

Yksityiskohtainen kuvaus

Kidney transplantation is performed 250-300 times annually in Denmark and substantially improves survival, quality of life, and reduces the burden of comorbidities in patients with end-stage kidney disease. Despite these benefits, vascular complications, particularly transplant renal artery stenosis (TRAS), remain a major cause of morbidity. Reported incidence of TRAS varies widely (1-23%), reflecting retrospective study designs and inconsistent diagnostic criteria. TRAS are classified into three main types: anastomotic (TRAS-A), post-anastomotic (TRAS-P), and long-segment bend/kink (TRAS-B), with most cases diagnosed within the first two years post-transplant. Severe stenoses can critically impair graft perfusion, leading to reduced renal function and treatment-resistant hypertension.

Percutaneous transluminal angioplasty (PTA) for TRAS is a well-established procedure performed according to the same principles as coronary balloon angioplasty; however, the role of stent placement remains uncertain. PTA without stenting is associated with higher restenosis rates compared to PTA with stenting, yet evidence regarding graft function, survival, and blood-pressure control remains conflicting.

Adverse events related to PTA occur in approximately 10% of patients and are generally mild. Serious adverse events are observed in fewer than 5% of patients and include procedure-related internal bleeding and vascular access-site complications. Severe internal bleeding may require blood transfusion and endovascular vessel occlusion and can, in rare cases, result in loss of the transplanted kidney. Access-site vascular complications may present as bleeding, thrombosis, or pseudoaneurysm.

Against this background, the nationwide prospective multicentre DAN-PTRAIII study aims to establish the true incidence of arterial inflow and venous outflow problems in Danish kidney-transplant recipients, evaluate the efficacy and safety of balloon angioplasty, and explore novel imaging and functional diagnostic methods for predicting treatment response.

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Arvioitu)

60

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

  • Nimi: Mark Reinhard, MD, PhD
  • Puhelinnumero: +45 40460321
  • Sähköposti: markrein@rm.dk

Tutki yhteystietojen varmuuskopiointi

Opiskelupaikat

      • Aarhus, Tanska, 8200
        • Rekrytointi
        • Aarhus University Hospital
        • Ottaa yhteyttä:
      • Copenhagen, Tanska, 2100
      • Odense, Tanska, 5000
        • Rekrytointi
        • Odense University Hospital
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Näytteenottomenetelmä

Ei-todennäköisyysnäyte

Tutkimusväestö

National prospective multicenter study with a primary endpoint at 3 months and annual follow-up for up to 10 years post-intervention, evaluating renal function, blood pressure, and clinical events.

Patients with vascular complications, predominantly transplant renal artery stenosis (TRAS) following kidney transplantation, who meet at least one of the clinical inclusion criteria, may be enrolled in the study.

Kuvaus

Inclusion Criteria:

1. At least one of the following clinical criteria (1 or 2) must be fulfilled:

  1. Graft dysfunction, defined by at least one of the following:

    • Acute reduction in estimated glomerular filtration rate (eGFR) >15% on two consecutive measurements at least 2 weeks apart, with other causes excluded (rejection, obstruction, infection).
    • eGFR <50% of the expected value 30 days after kidney transplantation of unknown cause.
    • Decline in eGFR >30% after initiation of an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.
  2. Persistent resistant hypertension for more than 6 weeks after kidney transplantation, defined as:

    • 24-hour ambulatory systolic blood pressure >130 mmHg despite treatment with at least three classes of antihypertensive medication at maximally tolerated doses (including diuretics, if tolerated).

Together with at least one of the following radiological criteria:

  1. CT or MR angiography demonstrating a lumen reduction ≥50%.

  2. Doppler ultrasound showing:

    1. Peak systolic velocity in the renal artery ≥200 cm/s and a renal-renal ratio (velocity at stenosis / velocity in distal artery) >4.
    2. Acceleration time >70 ms in intrarenal arteries.

2. In cases of strong clinical suspicion of a vascular complication where CT or MR angiography cannot reliably exclude graft artery or vein stenosis, patients may be referred for confirmatory invasive investigations.

Before PTA, catheter-based angiography and translesional pressure measurements are performed to confirm whether the patient meets the radiological eligibility criterion for PTA:

  1. Stenosis ≥70%.

  2. Stenosis 50-69% if at least one of the following criteria is met:

    • Mean translesional pressure gradient ≥10 mmHg.
    • Systolic pressure gradient ≥20 mmHg.
    • Renal Pd/Pa ≤0.8.
    • If pressure measurements cannot be obtained, treatment is based on the operator's clinical judgement.

Exclusion Criteria:

  1. Inability to provide informed consent.
  2. Concurrent biopsy demonstrating rejection requiring treatment.
  3. Pregnancy.
  4. Previous PTA of the same vessel.
  5. Patients unable to tolerate any form of antithrombotic therapy and therefore not eligible for stent placement.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Havaintomallit: COHORT
  • Aikanäkymät: PROSPECTIVE

Kohortit ja interventiot

Ryhmä/Kohortti
Interventio / Hoito
Kidney Transplant Recipients

Patients who meet well-defined clinical and radiological criteria for significant vascular complications after kidney transplantation, with transplant renal artery stenosis being by far the most common.

Catheter-based angiography performed in accordance with the study protocol.

Measurement of translesional pressure gradients performed in accordance with the study protocol.

Intravascular ultrasound (IVUS) performed in accordance with the study protocol.

Percutaneous transluminal angioplasty (PTA) is performed in accordance with the study protocol. As a general principle, bare-metal stents (BMS) are used. Drug-eluting stents (DES) may be considered when the arterial lumen diameter is < 4-5 mm. In stenoses where stent placement carries a risk of side-branch occlusion, PTA is performed without stent implantation and most often with a drug-coated balloon (DCB).

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in measured glomerular filtration rate (mGFR).
Aikaikkuna: Baseline and 3 months post-PTA.

Change in measured glomerular filtration rate (mGFR) at 3 months post-PTA compared with baseline.

Baseline and 3 months post-PTA.

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Change in estimated glomerular filtration rate (eGFR).
Aikaikkuna: Baseline, Day 1, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.

Change in estimated glomerular filtration rate (eGFR) measured on day 1, day 7, day 21, at 6 weeks, at 3 and 12 months, and annually thereafter for up to 10 years post-PTA, compared with baseline.

Baseline, Day 1, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.
Change in home systolic blood pressure.
Aikaikkuna: Baseline, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.

Change in home systolic blood pressure measured on day 7, day 21, at 6 weeks, at 3 and 12 months, and annually thereafter for up to 10 years post-PTA, compared with baseline.

Baseline, Day 7, Day 21, 6 weeks, 3 months, 12 months, and annually thereafter for up to 10 years post-PTA.
Change in attended automated office systolic blood pressure.
Aikaikkuna: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in attended automated office systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in unattended automated office systolic blood pressure.
Aikaikkuna: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in unattended automated office systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in 24-hour ambulatory systolic blood pressure.
Aikaikkuna: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in 24-hour ambulatory systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in defined daily dose (DDD) of antihypertensive medications.
Aikaikkuna: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in defined daily dose (DDD) of antihypertensive medications at 3, 12, and 24 months post-PTA compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in the number of antihypertensive medications.
Aikaikkuna: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in the number of antihypertensive medications at 3, 12, and 24 months post-PTA compared with baseline.

Baseline, 3 months, 12 months, and 24 months post-PTA.
Change in 24-hour ambulatory systolic blood pressure adjusted for changes in antihypertensive medication.
Aikaikkuna: Baseline, 3 months, 12 months, and 24 months post-PTA.

Change in 24-hour ambulatory systolic blood pressure measured at 3, 12, and 24 months post-PTA, compared with baseline, adjusted for changes in antihypertensive medication (5 mmHg per DDD).

Baseline, 3 months, 12 months, and 24 months post-PTA.
Health status on 12-item Short Form Health Survey (SF-12).
Aikaikkuna: Baseline and 3 months post-PTA.

Change in 12-item Short Form Health Survey (SF-12) scores at 3 months post-PTA, compared with baseline.

Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.

Baseline and 3 months post-PTA.
Number of clinical events after PTA.
Aikaikkuna: 10 years post-PTA.

Cardiovascular and renal events are defined according to the criteria used in the DAPA-CKD study, with the modification that end-stage kidney disease is defined exclusively as either kidney transplantation or chronic dialysis. After PTA treatment, the following clinical events will be recorded for 10 years:

  1. Cardiovascular death
  2. Renal death
  3. Death from non-cardiovascular and non-renal causes
  4. Undetermined cause of death
  5. Stroke
  6. Myocardial infarction
  7. Hospitalization for heart failure
  8. Reduction in eGFR ≥50% from baseline for ≥28 days, not fulfilling the definition of end-stage kidney disease
  9. End-stage kidney disease, defined as kidney transplantation or chronic dialysis for ≥28 days
  10. Biopsy-proven rejection
  11. Need for repeat PTA due to restenosis or in-stent thrombosis
  12. Other relevant clinical events
10 years post-PTA.
Number of adverse events (AEs) occurring within 30 days after the procedure
Aikaikkuna: 30 days post-PTA.

All adverse events (AEs) occurring within 30 days after the procedure will be recorded and classified according to seriousness, relationship to the procedure, and whether the event occurs within ≤24 hours (periprocedural) or >24 hours through day 30 (post-interventional):

  1. Vessel rupture
  2. Vessel dissection
  3. Vessel occlusion
  4. Vessel perforation
  5. Stent thrombosis
  6. Embolic events to the kidney or the peripheral circulation (upper or lower extremity, depending on the access route)
  7. Pulmonary oedema
  8. Major bleeding requiring transfusion
  9. Embolisation due to bleeding or another adverse event
  10. Nephrectomy due to bleeding or another adverse event
  11. Access-site or access-vessel complication requiring additional hospitalisation, blood transfusion, or surgical intervention
  12. Requirement for acute dialysis
  13. Clinical events, including all-cause mortality, as defined above
  14. Other relevant adverse events (AEs)
30 days post-PTA.
Doppler ultrasound.
Aikaikkuna: Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.
Invasive pressure measurements across stenoses.
Aikaikkuna: Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.
Intravascular ultrasound.
Aikaikkuna: Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.
Non-invasive fractional flow reserve computed tomography (FFR-CT) / computational fluid dynamics (CFD) simulation.
Aikaikkuna: Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.
Functional magnetic resonance imaging.
Aikaikkuna: Baseline and 3 months post-PTA.

Diagnostic utility and predictive value for treatment response to PTA.

Baseline and 3 months post-PTA.

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Perjantai 22. toukokuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Maanantai 31. maaliskuuta 2031

Opintojen valmistuminen (Arvioitu)

Sunnuntai 1. kesäkuuta 2031

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Keskiviikko 1. huhtikuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Maanantai 13. huhtikuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Keskiviikko 15. huhtikuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Perjantai 16. lokakuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 12. lokakuuta 2026

Viimeksi vahvistettu

Perjantai 1. toukokuuta 2026

Lisää tietoa

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa